The Healthcare Stage I Episode 4 I A Dairy-Derived Solution developed by Exosomm for IBD Relief.

This episode is dedicated to an Israeli food-tech startup named Exosomm, established in 2021. The company’s first product is a proprietary formula for Inflammatory Bowel Diseases (IBD), containing milk exosomes derived from cow milk.

The scientific basis for this company originates from many years of research conducted at Hadassah Medical Center, which generated robust evidence demonstrating the anti-inflammatory activity of mammals’ milk-derived exosomes. These findings were shown in multiple preclinical studies in both IBD models but also in additional indications.

Their first product, regulated as food, is intended for use in ulcerative colitis and Crohn’s patients, for both maintenance and flare periods, and is aimed at reducing gut inflammation and improve the patient’s quality of life.

As of company establishment and up to the beginning of 2024, the company was able to achieve significant milestones, Including the development of exosomes-extraction methodology, important IP, initial regulatory approval, and partnership with Tnuva- a leading food company in Israel which will be their 1^st commercial partner in Israel. This agreement also allows Exosomm to extract the exosomes and scale up the production process in Tnuva’s manufacturing facility.

Exosomm raised up until now $1.1M from several Investors including AgFunder, Clalit health services, which owns 60% of the hospitals in Israel and Tnuva, a key player in the Israeli dairy market. They are now looking to raise a bridge round of $1M to achieve their 2024 milestones.